Emerge Diagnostics, a San Diego, CA-based provider of functional EMG technology for the diagnosis and treatment of soft tissue injuries, raised $3m in financing.
The backers were not disclosed.
The company intends to use the funds to expand its sales force and clinic network to meet the demand from employers nationwide.
Led by Robert Thompson, CEO, Emerge Diagnostics provides the Electrodiagnostic Functional Assessment (EFA) test, an FDA Class II medical device that enables employers and occupational health clinics to diagnose and identify the location, extent, nature and age of soft tissue injuries of the back, neck, shoulder, and extremities, including repetitive strain injuries. The test determines the injured muscle group as well as compliance, malingering and pain.
Its EFA-STM Program measures current and new employees before and after workplace injuries to assist in determining if an injury arose out of the course and scope of employment. It determines pre-injury status and whether there is a change in condition after the reported injury.